These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9706431)

  • 41. Hydroxychloroquine-induced pruritus.
    Holme SA; Holmes SC
    Acta Derm Venereol; 1999 Jul; 79(4):333. PubMed ID: 10430003
    [No Abstract]   [Full Text] [Related]  

  • 42. Woman in grey: hydroxychloroquine-induced hyperpigmentation.
    Ivo R; Lopes CA; Reis R
    BMJ Case Rep; 2018 Nov; 11(1):. PubMed ID: 30567137
    [No Abstract]   [Full Text] [Related]  

  • 43. [Pleading to maintain hydroxychloroquine throughout Lupus pregnancies].
    Costedoat-Chalumeau N; Amoura Z; Le Thi Huong D; Wechsler B; Piette JC
    Rev Med Interne; 2005 Jun; 26(6):467-9. PubMed ID: 15936475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful desensitization for hydroxychloroquine anaphylaxis.
    Donado CD; Díez EM
    J Rheumatol; 2010 Sep; 37(9):1975-6. PubMed ID: 20810530
    [No Abstract]   [Full Text] [Related]  

  • 45. Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine.
    Zhang S; Liu X; Cai L; Zhang J; Zhou C
    Lupus; 2019 Jan; 28(1):129-132. PubMed ID: 30428763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diplopia in a patient under hydroxychloroquine for systemic lupus erythematosus.
    Sabbagh M
    Rev Rhum Engl Ed; 1997 Jan; 64(1):65. PubMed ID: 9051865
    [No Abstract]   [Full Text] [Related]  

  • 47. Evidence for risk of cardiomyopathy with hydroxychloroquine.
    Sumpter MD; Tatro LS; Stoecker WV; Rader RK
    Lupus; 2012 Dec; 21(14):1594-6. PubMed ID: 23036986
    [No Abstract]   [Full Text] [Related]  

  • 48. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study.
    Leroux M; Desveaux C; Parcevaux M; Julliac B; Gouyon JB; Dallay D; Pellegrin JL; Boukerrou M; Blanco P; Lazaro E
    Lupus; 2015 Nov; 24(13):1384-91. PubMed ID: 26082465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hydroxychloroquine-related skin discoloration.
    Coulombe J; Boccara O
    CMAJ; 2017 Feb; 189(5):E212. PubMed ID: 26903361
    [No Abstract]   [Full Text] [Related]  

  • 50. Hydroxychloroquine-Induced Erythema Multiforme.
    Abou Assalie N; Durcan R; Durcan L; Petri MA
    J Clin Rheumatol; 2017 Mar; 23(2):127-128. PubMed ID: 28099213
    [No Abstract]   [Full Text] [Related]  

  • 51. [Renal infarction in systemic lupus with antiphospholipid syndrome: role of hydroxychloroquine withdrawal? Comment on the article by Szymezak et al].
    Zenone T; Knefati Y
    Rev Med Interne; 2011 Apr; 32(4):261-2. PubMed ID: 21330018
    [No Abstract]   [Full Text] [Related]  

  • 52. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
    Pelle MT; Callen JP
    Arch Dermatol; 2002 Sep; 138(9):1231-3; discussion 1233. PubMed ID: 12224986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of hydroxychloroquine in Japan.
    Kishimoto M; Deshpande GA; Yokogawa N; Buyon JP; Okada M
    J Rheumatol; 2012 Jun; 39(6):1296. PubMed ID: 22661421
    [No Abstract]   [Full Text] [Related]  

  • 54. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
    Ezra N; Jorizzo J
    Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients.
    Sonigo G; Jachiet M; Bessis D; Cordel N; Faucon C; Petit A; Cordoliani F; Bagot M; Senet P; Barbaud A; Bouaziz JD; Francès C; Chasset F;
    J Am Acad Dermatol; 2022 Jul; 87(1):203-206. PubMed ID: 34333080
    [No Abstract]   [Full Text] [Related]  

  • 56. Nonlupus nephritis in an adolescent with systemic lupus erythematosus.
    Turkmen M; Soylu A; Demir K; Kasap B; Sarioglu S; Kavukcu S
    Lupus; 2005; 14(2):171-3. PubMed ID: 15751825
    [No Abstract]   [Full Text] [Related]  

  • 57. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus.
    Wolfe F; Marmor MF
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):775-84. PubMed ID: 20535788
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
    Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
    Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plaque-like Cutaneous Lupus Mucinosis as the First Sign of Systemic Lupus Erythematosus.
    Gao M; Sheng N; Yang X; Jiang Y
    Acta Derm Venereol; 2020 Feb; 100(4):adv00048. PubMed ID: 31774542
    [No Abstract]   [Full Text] [Related]  

  • 60. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.